The use of prostate-specific membrane antigen (PSMA)-directed applications in modern
prostate cancer management has evolved rapidly over the past few years, helping to …

Introduction In the last decade, two new radionuclide-based therapies, 223Radichloride and
radioligand therapy (RLT) targeting prostate-specific membrane antigen (PSMA), have been …

Despite the potential of deep learning (DL)-based methods in substituting CT-based PET
attenuation and scatter correction for CT-free PET imaging, a critical bottleneck is their …

Background: prostate-specific membrane antigen (PSMA) ligand PET has been recently
incorporated into international guidelines for several different indications in prostate cancer …

Background and objective Treatment planning through the diagnostic dimension of
theranostics provides insights into predicting the absorbed dose of RPT, with the potential to …

Prostate cancer (PCa) is the third most common cancer diagnosed in the world, with 1.4
million cases diagnosed and approximately 375,000 men reported dead in 2020. 1 …

Bone metastasis is the unavoidable clinical challenge for oncologists. Unbearable bone
pain and functional loss caused by pathological fractures are often the reasons why patients …

We present an 87-year-old man diagnosed with prostate cancer and neuroendocrine
differentiation, posttherapy results to consecutive 177 Lu–prostate-specific membrane …